Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 3 | 2023 | 2847 | 0.790 |
Why?
|
| Medical Oncology | 2 | 2021 | 229 | 0.780 |
Why?
|
| Thrombocytosis | 1 | 2022 | 33 | 0.750 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 479 | 0.730 |
Why?
|
| Cerebellar Neoplasms | 1 | 2024 | 315 | 0.690 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 219 | 0.690 |
Why?
|
| Medulloblastoma | 1 | 2024 | 379 | 0.670 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 222 | 0.670 |
Why?
|
| Hematology | 1 | 2018 | 40 | 0.570 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 72 | 0.560 |
Why?
|
| Immunophenotyping | 1 | 2018 | 331 | 0.550 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2021 | 555 | 0.510 |
Why?
|
| Global Health | 2 | 2021 | 605 | 0.510 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 786 | 0.510 |
Why?
|
| Flow Cytometry | 1 | 2018 | 758 | 0.500 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 294 | 0.460 |
Why?
|
| Child | 20 | 2024 | 25061 | 0.460 |
Why?
|
| HIV Infections | 3 | 2022 | 1948 | 0.450 |
Why?
|
| Africa South of the Sahara | 4 | 2023 | 114 | 0.410 |
Why?
|
| Anemia, Sickle Cell | 3 | 2022 | 325 | 0.400 |
Why?
|
| Uganda | 3 | 2024 | 94 | 0.400 |
Why?
|
| Developing Countries | 2 | 2024 | 298 | 0.330 |
Why?
|
| Pediatrics | 1 | 2018 | 1202 | 0.300 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2024 | 222 | 0.290 |
Why?
|
| Humans | 25 | 2024 | 126020 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2016 | 152 | 0.230 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2022 | 226 | 0.220 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 657 | 0.220 |
Why?
|
| Nevirapine | 1 | 2022 | 14 | 0.190 |
Why?
|
| Lamivudine | 1 | 2022 | 20 | 0.190 |
Why?
|
| Platelet Count | 1 | 2022 | 130 | 0.190 |
Why?
|
| Pancytopenia | 1 | 2021 | 40 | 0.170 |
Why?
|
| Injection Site Reaction | 1 | 2021 | 7 | 0.170 |
Why?
|
| Child, Preschool | 8 | 2024 | 14330 | 0.160 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 216 | 0.160 |
Why?
|
| Bone Marrow Cells | 1 | 2021 | 234 | 0.160 |
Why?
|
| Global Burden of Disease | 1 | 2019 | 27 | 0.160 |
Why?
|
| Rituximab | 1 | 2021 | 165 | 0.160 |
Why?
|
| Anaphylaxis | 1 | 2021 | 86 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2021 | 182 | 0.150 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 154 | 0.150 |
Why?
|
| Neutropenia | 1 | 2021 | 198 | 0.150 |
Why?
|
| Retrospective Studies | 5 | 2024 | 16753 | 0.150 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 132 | 0.150 |
Why?
|
| Capacity Building | 1 | 2018 | 21 | 0.150 |
Why?
|
| Wilms Tumor | 1 | 2019 | 116 | 0.140 |
Why?
|
| Patient Care | 1 | 2018 | 99 | 0.140 |
Why?
|
| Osteopontin | 1 | 2018 | 51 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3303 | 0.140 |
Why?
|
| Incidence | 3 | 2020 | 3212 | 0.130 |
Why?
|
| Poverty | 1 | 2021 | 429 | 0.130 |
Why?
|
| Adolescent | 8 | 2024 | 19936 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 487 | 0.130 |
Why?
|
| Lymphoma | 2 | 2021 | 317 | 0.130 |
Why?
|
| Male | 12 | 2024 | 62050 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2019 | 256 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 204 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 1024 | 0.120 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2015 | 5 | 0.120 |
Why?
|
| Radon | 1 | 2015 | 10 | 0.120 |
Why?
|
| Infant | 6 | 2021 | 12762 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 660 | 0.120 |
Why?
|
| Young Adult | 5 | 2021 | 9615 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 435 | 0.120 |
Why?
|
| Air Pollution, Indoor | 1 | 2015 | 34 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 314 | 0.120 |
Why?
|
| Risk Factors | 4 | 2022 | 10386 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1302 | 0.110 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 272 | 0.110 |
Why?
|
| Female | 11 | 2024 | 67877 | 0.110 |
Why?
|
| Sarcoma, Kaposi | 1 | 2016 | 123 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 291 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 532 | 0.100 |
Why?
|
| Prognosis | 1 | 2022 | 4707 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1706 | 0.090 |
Why?
|
| Pericardial Effusion | 1 | 2012 | 72 | 0.090 |
Why?
|
| Stomatitis, Aphthous | 1 | 2011 | 2 | 0.090 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2012 | 149 | 0.090 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 137 | 0.090 |
Why?
|
| Atrioventricular Block | 1 | 2011 | 44 | 0.090 |
Why?
|
| Creatinine | 2 | 2022 | 378 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 237 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 1223 | 0.070 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2012 | 357 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 1845 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 1349 | 0.070 |
Why?
|
| Herpesvirus 4, Human | 2 | 2021 | 613 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 1124 | 0.050 |
Why?
|
| Lipocalin-2 | 1 | 2022 | 26 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2022 | 42 | 0.050 |
Why?
|
| Lipocalins | 1 | 2022 | 31 | 0.050 |
Why?
|
| Child, Hospitalized | 1 | 2022 | 77 | 0.040 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2021 | 16 | 0.040 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 12 | 0.040 |
Why?
|
| Biomarkers | 2 | 2022 | 3137 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 116 | 0.040 |
Why?
|
| Agammaglobulinemia | 1 | 2021 | 43 | 0.040 |
Why?
|
| Nephrotic Syndrome | 1 | 2021 | 49 | 0.040 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2021 | 36 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 175 | 0.040 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 52 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 171 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 144 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 200 | 0.040 |
Why?
|
| Vincristine | 1 | 2020 | 190 | 0.040 |
Why?
|
| Encephalitis | 1 | 2021 | 117 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 52 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 101 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 273 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 518 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 588 | 0.040 |
Why?
|
| Social Class | 1 | 2019 | 198 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 420 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 514 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2021 | 1188 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 806 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2021 | 223 | 0.030 |
Why?
|
| Texas | 2 | 2016 | 3532 | 0.030 |
Why?
|
| Time Factors | 2 | 2021 | 6006 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 373 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 344 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 336 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1476 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 300 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 192 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8357 | 0.030 |
Why?
|
| Herpesvirus 8, Human | 1 | 2016 | 46 | 0.030 |
Why?
|
| Inhalation Exposure | 1 | 2015 | 33 | 0.030 |
Why?
|
| Housing | 1 | 2015 | 52 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 2059 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1060 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1234 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 500 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2099 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 726 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 1476 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 2936 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 4306 | 0.020 |
Why?
|
| Adult | 3 | 2018 | 30235 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 76 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 4914 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2011 | 119 | 0.020 |
Why?
|
| Exercise Test | 1 | 2011 | 239 | 0.020 |
Why?
|
| Pacemaker, Artificial | 1 | 2011 | 184 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 565 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 458 | 0.020 |
Why?
|
| Echocardiography | 1 | 2012 | 1097 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 3032 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2011 | 918 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2026 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12310 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 1024 | 0.010 |
Why?
|
| United States | 1 | 2016 | 11198 | 0.010 |
Why?
|